OverviewSuggest Edit
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.
OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.
| Type | Public | |
| Founded | 2008 | |
| HQ | San Diego, CA, US | Map |
| Website | otonomy.com |
Recent NewsAll News
- Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
- Otonomy to Participate in Three Upcoming Investor Conferences
- Otonomy stock loses half its value after disappointing trial results of vertigo treatment
- Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
Key People/Management at Otonomy
David A. Weber
Chief Executive Officer, President and Board Member
Carla da Luz Boren
General Counsel and Head of Human Resources
Julie D. Burgess
Vice President, Finance and Administration
Paul E. Cayer
Chief Financial & Business Officer
David Skarinsky
Vice President, Clinical
Barbara M. Finn
Vice President, Regulatory Affairs and Quality Assurance
Otonomy Office Locations
Otonomy has an office in San Diego
San Diego, CA, US (HQ)
4796 Executive Dr
Otonomy Financials and Metrics
Otonomy Revenue
Otonomy's revenue was reported to be $273 k in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 273.0k |
Gross profit (FY, 2020) | (915.0k) |
Gross profit margin (FY, 2020), % | (335.2%) |
Net income (FY, 2020) | (44.7m) |
EBIT (FY, 2020) | (43.5m) |
Market capitalization (30-Mar-2021) | 120.3m |
Closing stock price (30-Mar-2021) | 2.5 |
Cash (31-Dec-2020) | 30.8m |
EV | 104.7m |
Otonomy's current market capitalization is $120.3 m.
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 358.0k | 326.0k | 282.0k | 301.0k | 123.0k | 113.0k | 192.0k | 190.0k | 125.0k | 160.0k | 10.0k | 50.0k |
Cost of goods sold | 463.0k | 397.0k | 290.0k | 272.0k | 241.0k | 162.0k | 213.0k | 203.0k | 220.0k | 214.0k | 511.0k | 189.0k |
Gross profit | (105.0k) | (71.0k) | (8.0k) | 29.0k | (118.0k) | (49.0k) | (21.0k) | (13.0k) | (95.0k) | (54.0k) | (501.0k) | (139.0k) |
Gross profit Margin, % | (29%) | (22%) | (3%) | 10% | (96%) | (43%) | (11%) | (7%) | (76%) | (34%) | (5010%) | (278%) |
- Source: SEC Filings
Annual
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (27.1m) | (71.3m) | (11.4m) | (25.0m) | (37.5m) | (12.0m) | (23.7m) | (33.7m) | (11.8m) | (23.2m) | (34.1m) | |
Depreciation and Amortization | 923.0k | 295.0k | 594.0k | 892.0k | 276.0k | 565.0k | 854.0k | 286.0k | 569.0k | 843.0k | ||
Inventories | 1.2m | 1.2m | 197.0k | 6.0k | ||||||||
Accounts Payable | 212.0k | 1.3m | 138.0k | 1.5m | (184.0k) | 321.0k | 123.0k | 837.0k | (90.0k) | (264.0k) | (491.0k) | (655.0k) |
- Source: SEC Filings
| USD | FY, 2016 |
|---|---|
Revenue/Employee | 4.9k |
Financial Leverage | 1.1 x |
Otonomy Operating Metrics
| FY, 2016 | |
|---|---|
Patents Issued | 88 |
Patents Pending | 115 |
Phase III Trials Products | 2 |
Products | 1 |
Otonomy Cybersecurity Score
Otonomy Environment, Social & Governance (ESG) Ratings
Otonomy Online and Social Media Presence
213 Twitter followers
Otonomy has 213 Twitter Followers. The number of followers has decreased 0.2% month over month and decreased 3.9% quarter over quarter
Otonomy's Trends
Otonomy News and Updates
March 25, 2021
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. The randomize…
February 25, 2021
Otonomy to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in three upcoming virtual conferences:
February 22, 2021
Otonomy stock loses half its value after disappointing trial results of vertigo treatment
Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and …
February 22, 2021
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary…
February 11, 2021
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET
February 04, 2021
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update …
Otonomy Blogs
September 02, 2020
Otonomy to Participate in Four Upcoming Investor Conferences
Otonomy to Participate in Four Upcoming Investor Conferences
Content Import
Wed, 09/02/2020 - 07:30
Otonomy to Participate in Four Upcoming Investor Conferences
September 2, 2020 at 7:30 AM EDT
This release is a backfill from a News Wire
General…
July 28, 2020
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Content Import
Tue, 07/28/2020 - 16:06
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 28, 2020 at 4:05 PM EDT
This release is a back…
July 13, 2020
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Content Import
Mon, 07/13/2020 - 16:01
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Ju…
July 09, 2020
Otonomy Announces Pricing of $60.1 Million Public Offering
SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the
July 08, 2020
Otonomy Announces Proposed Public Offering
SAN DIEGO , July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock.
July 06, 2020
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
Content Import
Mon, 07/06/2020 - 16:04
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
July 6, 2020 at 4:…
Otonomy Frequently Asked Questions
When was Otonomy founded?
Otonomy was founded in 2008.
Who are Otonomy key executives?
Otonomy's key executives are David A. Weber, Carla da Luz Boren and Julie D. Burgess.
How many employees does Otonomy have?
Otonomy has 49 employees.
What is Otonomy revenue?
Latest Otonomy annual revenue is $273 k.
What is Otonomy revenue per employee?
Latest Otonomy revenue per employee is $5.6 k.
Who are Otonomy competitors?
Competitors of Otonomy include Seed Health, BeyondSpring and Alembic Pharmaceuticals.
Where is Otonomy headquarters?
Otonomy headquarters is located at 4796 Executive Dr, San Diego.
Where are Otonomy offices?
Otonomy has an office in San Diego.
How many offices does Otonomy have?
Otonomy has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies